DENN domain containing 4AGenealiases: IRLB · MYCPBP
Q-omics provides the consensus-scored DENND4A profile across patient tissues and cancer cell-line models. DENND4A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DENND4A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, DENND4A RNA expression shows 21,206 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where DENND4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND4A survival associations across molecular data types. DENND4A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND4A RNA expression–survival associations across cancer types. High DENND4A expression shows unfavorable associations in UVM and ESCA, but favorable associations in KIRC, SKCM, LUAD and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DENND4A RNA expression.
This table summarizes DENND4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DENND4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND4A shows lower tumor expression in UCEC, LUAD, THCA and READ and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher DENND4A RNA expression in tumor versus normal tissue (log2 FC = +0.686, t-test p < 0.001).
This table shows molecular features associated with DENND4A in patient tissues and cancer cell lines. In patient samples, DENND4A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
